Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Key strategy to limit managed care drug costs failing, survey shows

15.09.2005


With rising concern over the cost of the new Medicare prescription drug benefit program – going into effect January, 2006 and estimated to cost $593 billion over the next decade – a new UCSF study reveals that a key cost-cutting strategy employed by HMOs for 15 years is simply not working.



Health insurance companies have increasingly sought to limit the amount of expensive drugs doctors prescribe to patients in order to keep drug costs form spiraling, according to the study authors. A major strategy has been to restrain drug costs by assuring that a medical group will make money if member doctors prescribe within the drug budget set by the insurance company, and will lose money if member doctors over-prescribe.

The underlying assumption is that placing doctors at financial risk for their drug prescribing practices will lead them to adopt new practices to control drug costs, the authors explain. These practices include hiring pharmacists for expert advice, using "physician profiling" to compare doctors’ prescribing patterns, and adhering to professional protocols that specify what each drug should be prescribed for, at what dose and for how long.


The new study shows that providing financial incentives for doctors to rein in their prescription practices has not led to cost-cutting innovations.

The study is being published in the August issue of the Journal of Health Policy, Politics and the Law, available mid-September. It is based on a survey of executives in more than three dozen physician groups and HMOs in four large U.S. cities.

The survey found widespread dissatisfaction with the HMO strategy of making doctors financially liable for prescription drug costs above a certain limit. It also found doctors were often confused or unaware of the incentives, either because of unclear contracts with HMOs or failure of HMOs to share drug cost information with doctors appropriately. In addition, frequent changes in the contract made it hard for physicians to know if an investment in innovation made under today’s deal would still pay off under tomorrow’s, the survey shows.

"The problem lies in the contract terms and information-sharing between the HMO and doctors. Fix that, and you’ll go a long way to controlling drug costs," says study co-author R. Adams Dudley, MD, UCSF associate professor of medicine and health policy.

HMOs negotiated their own prices for drugs with the manufacturers via pharmacy benefit managers but typically failed to disclose that information to physicians, the survey revealed.

"Profitably managing something as complex as prescription drug risk requires accurate, timely information, but most of the surveyed physician groups couldn’t even calculate their total drug costs," says Jonathan D. Agnew, PhD, a study co-author and senior policy consultant at the British Columbia Medical Association.

Even when HMOs were willing to share price information, the study found that the data usually got to the doctors too late for them to determine if they were over or under budget.

"On the one hand, doctors get too much information from working with so many HMOs, each with its own array of prescription drug benefits and policies. On the other hand, the information they do get from the HMO is often incomplete or not timely enough to help them make good management decisions," says Helene Levens Lipton, PhD, professor of health policy and pharmacy at UCSF and lead author of the study.

The survey also found that HMO contracts with physician groups focused far more on efforts to contain costs than to maintain or improve the quality of care, Dudley said.

The researchers propose three major changes:

  • Contracts between physician groups and HMOs should be clearer and more accurate, and information about changing drug-cost incentives should be provided to physicians in a more timely way.
  • Doctors should not be held liable for the costs of doing the "right thing": If giving a prescription is the right thing to do, the costs should not be included in a budget target. Rather, the expenditure targets should be limited to situations in which medication use is more discretionary, such as whether or not a patient needs to continue on anti-ulcer drugs after an ulcer has healed.
  • When HMOs evaluate a group’s performance, the assessment should be fair. For example, in the late 1990s, doctors should not have been penalized for rising prescription costs related to the introduction of new drug therapies they could not have budgeted for, such as the first drug therapies for attention deficit disorder.

As another example of a drug-risk contract considered unfair by physician groups, the authors report that one physician group was penalized for not controlling its costs as well as another group in the HMO’s network, even though the other group was in a different health care market.

Under the new Medicare drug benefit, reimbursement for HMOs depends, in part, on their establishing sound drug use management programs to contain drug costs, the authors point out.

"As HMOs establish and modify these programs, we hope the data presented here can help them avoid some of the major pitfalls we found in several large cities across the country," says study co-author Marilyn Stebbins, PharmD, UCSF professor of clinical pharmacy. "And doctors can learn to request fairer contracts and better information sharing."

Wallace Ravven | EurekAlert!
Further information:
http://www.ucsf.edu

More articles from Studies and Analyses:

nachricht Amputees can learn to control a robotic arm with their minds
28.11.2017 | University of Chicago Medical Center

nachricht The importance of biodiversity in forests could increase due to climate change
17.11.2017 | Deutsches Zentrum für integrative Biodiversitätsforschung (iDiv) Halle-Jena-Leipzig

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: First-of-its-kind chemical oscillator offers new level of molecular control

DNA molecules that follow specific instructions could offer more precise molecular control of synthetic chemical systems, a discovery that opens the door for engineers to create molecular machines with new and complex behaviors.

Researchers have created chemical amplifiers and a chemical oscillator using a systematic method that has the potential to embed sophisticated circuit...

Im Focus: Long-lived storage of a photonic qubit for worldwide teleportation

MPQ scientists achieve long storage times for photonic quantum bits which break the lower bound for direct teleportation in a global quantum network.

Concerning the development of quantum memories for the realization of global quantum networks, scientists of the Quantum Dynamics Division led by Professor...

Im Focus: Electromagnetic water cloak eliminates drag and wake

Detailed calculations show water cloaks are feasible with today's technology

Researchers have developed a water cloaking concept based on electromagnetic forces that could eliminate an object's wake, greatly reducing its drag while...

Im Focus: Scientists channel graphene to understand filtration and ion transport into cells

Tiny pores at a cell's entryway act as miniature bouncers, letting in some electrically charged atoms--ions--but blocking others. Operating as exquisitely sensitive filters, these "ion channels" play a critical role in biological functions such as muscle contraction and the firing of brain cells.

To rapidly transport the right ions through the cell membrane, the tiny channels rely on a complex interplay between the ions and surrounding molecules,...

Im Focus: Towards data storage at the single molecule level

The miniaturization of the current technology of storage media is hindered by fundamental limits of quantum mechanics. A new approach consists in using so-called spin-crossover molecules as the smallest possible storage unit. Similar to normal hard drives, these special molecules can save information via their magnetic state. A research team from Kiel University has now managed to successfully place a new class of spin-crossover molecules onto a surface and to improve the molecule’s storage capacity. The storage density of conventional hard drives could therefore theoretically be increased by more than one hundred fold. The study has been published in the scientific journal Nano Letters.

Over the past few years, the building blocks of storage media have gotten ever smaller. But further miniaturization of the current technology is hindered by...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

See, understand and experience the work of the future

11.12.2017 | Event News

Innovative strategies to tackle parasitic worms

08.12.2017 | Event News

AKL’18: The opportunities and challenges of digitalization in the laser industry

07.12.2017 | Event News

 
Latest News

Engineers program tiny robots to move, think like insects

15.12.2017 | Power and Electrical Engineering

One in 5 materials chemistry papers may be wrong, study suggests

15.12.2017 | Materials Sciences

New antbird species discovered in Peru by LSU ornithologists

15.12.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>